On the basis of this evidence, a recent ESICM consensus on fluid therapy in neurointensive care recommended the use of crystalloids as preferred maintenance fluids in brain-injured patients and avoidance of high-dose (20–25%) albumin during the acute phase of stroke (3). The gene discussed is ALB; the disease is Stroke.